Covalent CDK7 Inhibitor THZ1 Inhibits Myogenic Differentiation

Covalent CDK7 inhibitor THZ1 is a newly discovered anti-tumor drug.THZ1 affects the function of transcription factor TFIIH by inhibiting CDK7, which in turn affects RNA polymerase II, and ultimately affects transcription initiation. Study found that THZ1 could inhibit proliferation and promote apopt...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Cancer
Main Authors: Ma, Xinqi, Kuang, Xielan, Xia, Qing, Huang, Zixin, Fan, Yuting, Ning, Jie, Wen, Jiajie, Zhang, Han, Yan, Jianhua, Zhang, Qingjiong, Shen, Huangxuan, Long, Chongde
Formato: Artigo
Idioma:Inglês
Publicado em: Ivyspring International Publisher 2018
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6134829/
https://ncbi.nlm.nih.gov/pubmed/30210638
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.25395
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados